Kallikrein 1 (KLK1), also known as tissue kallikrein, is a serine protease encoded by the KLK1 gene. It plays a key role in the kallikrein-kinin system, catalyzing the cleavage of kininogen to produce bioactive kinins, such as bradykinin. These peptides regulate physiological processes, including blood pressure, inflammation, and electrolyte balance. KLK1 is predominantly expressed in the kidneys, pancreas, and salivary glands, and its activity is linked to cardiovascular homeostasis, renal function, and tissue repair. Dysregulation of KLK1 has been implicated in hypertension, diabetic nephropathy, and inflammatory disorders.
KLK1 antibodies are essential tools for studying its expression, localization, and function. They are widely used in immunoassays (e.g., ELISA, Western blot, immunohistochemistry) to quantify KLK1 levels in tissues or biofluids, aiding in research on disease mechanisms. Monoclonal antibodies offer high specificity for KLK1. distinguishing it from other kallikrein family members (KLK2-KLK15), while polyclonal antibodies may detect conserved epitopes across species. Recent studies explore KLK1's therapeutic potential, with antibodies serving to modulate its activity in preclinical models. However, cross-reactivity with homologous proteins remains a challenge, emphasizing the need for rigorous validation. Overall, KLK1 antibodies are pivotal in elucidating its roles in health and disease.